Gilead SciencesFRA:GIS -1.34%75 Operating Margin % is 38.68% as of Mar. 2026, which is 4% below its 10-year median of 40.22. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.28 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Gilead Sciences ranks better than 98.01% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Gilead Sciences Operating Margin % Related Terms
Gilead Sciences Operating Margin % Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs AMGN, PFE, BMY: Operating Margin % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Gilead Sciences's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Operating Margin % of 38.68% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Gilead Sciences and its competitors. This is near median its historical median of 40.22. Over the past decade, Gilead Sciences' Operating Margin % has ranged from 32.59 to 58.02. According to the industry distribution chart, Gilead Sciences ranks #19 out of 955 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Gilead Sciences' Operating Margin % too high?
Gilead Sciences' current Operating Margin % of 38.68% is near median its 10-year median of 40.22. Over the past 10 years, this metric has ranged from a low of 32.59 to a high of 58.02. The Drug Manufacturers industry median Operating Margin % is 7.45. Gilead Sciences' value of 38.68% is 419.2% above this industry median. Based on the distribution chart, Gilead Sciences ranks #19 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Operating Margin % compare to AMGN and PFE?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #19 out of 955 companies for Operating Margin %. This places Gilead Sciences in the top 2% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.45. Gilead Sciences' value of 38.68% is 419.2% above this benchmark. Historically, Gilead Sciences' own Operating Margin % has ranged from 32.59 to 58.02 over the past decade. While the company's 10-year median is 40.22 vs. the industry median of 7.45, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Operating Margin % of 38.68% is 419.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Operating Margin % is 38.68%, which is near median its own 10-year median of 40.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.28, compared to a current price of €109.12 — trading 32.6% above its estimated fair value. The current Operating Margin % is 38.68%, which is near median its 10-year median of 40.22 and 419.2% above the Drug Manufacturers industry median of 7.45. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Operating Margin % is 38.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €109.12 is trading 32.6% above its estimated GF Value™ of €82.28.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Operating Margin %: 38.68% (near median its 10-year median of 40.22)
GF Value™: €82.28 vs. price of €109.12 (32.6% above fair value)
Industry Position: 419.2% above the Drug Manufacturers median (#19 of 955)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
